-
Mashup Score: 3
ASCO 2023, prostate cancer, Prostate specific antigen (PSA) SPARTAN trial, PROSPER trial, ARAMIS trial, Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), prostate cancer disease extent, PSMA-PET as prostate cancer treatment.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0ASCO 2023: DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States - 11 month(s) ago
ASCO 2023 DEAR trial prostate cancer, DEAR comparative real-world evidence study of darolutamide, enzalutamide, and apalutamide for patients with nmCRPC in the United States
Source: www.urotoday.comCategories: Latest Headlines, UrologyTweet-
#DEAR Comparative real-world evidence on darolutamide, enzalutamide, and apalutamide for patients with #nmCRPC in the #UnitedStates. Presented by @CaPsurvivorship @DanaFarber. #ASCO23 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/knX2T3V6Kd @ASCO https://t.co/QN832KNiSd
-
-
Mashup Score: 0Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer - 12 month(s) ago
For patients with non-metastatic castration resistant prostate cancer, this clinical trial compared the androgen receptor antagonist flutamide with or without P
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this RCT involving men with #nmCRPC with rising PSA on #ADT, the combination of #flutamide + #PROSTVAC (pox viral vaccine targeting PSA) was well-tolerated but did not improve clinical or immunologic outcomes vs. flutamide alone. @Dr_RaviMadan https://t.co/jaNwKFv2OA https://t.co/rVQaUQVEbg
-
-
Mashup Score: 6AUA 2023: Treatment Duration and Long-term Safety and Tolerability With Darolutamide in nmCRPC: ARAMIS Rollover Study - 1 year(s) ago
AUA 2023 ARAMIS Rollover Study, treatment duration and long-term safety and tolerability with darolutamide in nmCRPC, patients with nmCRPC, darolutamide in nmCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Treatment duration and long-term safety and tolerability with darolutamide in #nmCRPC: #ARAMIS rollover study. Presented by Neal Shore, MD, FACS @AtlanticUrology. #AUA23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/GpU4WwXT51 @AmerUrological https://t.co/a1XpnVh9JP
-
-
Mashup Score: 0
Dr. Sternberg shares the therapeutic options for patients with nmCRPC, how stage at diagnosis impacts treatment options, and more.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We spoke with Cora Sternberg, MD (@cnsternberg), from @WeillCornell and @nyphospital, on several influential #nmCRPC clinical trials, as well as the therapeutic options available for patients with nmCRPC. Watch now: https://t.co/Mvm5HC7Hir https://t.co/c51jZ7cc3d
-
-
Mashup Score: 0
A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Apalutamide is now available in US in a 240 mg once-daily tablet for the treatment of patients with #nmCRPC and #mCSPC. #pcsm #FDA | @neerajaiims @huntsmancancer https://t.co/cuOo4nm9HV https://t.co/wN5hkbJ17i
-
-
Mashup Score: 0
Researchers conducted a study to determine PSA response and MFS in patients with nmCRPC treated with APA and compared their results with the SPARTAN trial.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Apalutamide and androgen deprivation therapy is a common treatment combination for patients with #nmCRPC, but how does the treatment affects patients who have already received APA? Researchers from @ChesUrology conducted a study to learn more: https://t.co/mT2MQNgrgU https://t.co/fLzVq1Id4D
-
-
Mashup Score: 6ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study - 1 year(s) ago
ASCO GU 2023 ARAMIS Rollover Study, safety and tolerability of darolutamide, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide treatment in the ARAMIS Rollover Study,
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Long-term safety and tolerability of darolutamide and duration of treatment in patients with #nmCRPC from the #ARAMIS rollover study. Presented by Neal Shore, MD, FACS @AtlanticUrology. @ASCO #GU23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/28y48jfLDB https://t.co/jGNSkMMCi1
-
-
Mashup Score: 2
ASCO GU 2023 darolutamide for non-metastatic castrate resistant prostate cancer (nmCRPC), data from the ARAMIS trial, RECORD study, nmCRPC in the UK, NICE for Darolutamide.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world prospective evaluation of clinical outcomes in patients with #nmCRPC treated with darolutamide. Presented by Amarnath Challapalli @uhbwNHS. @ASCO #GU23 written coverage by @WallisCJD @UofT > https://t.co/2uEwv9pTgT https://t.co/Me5oPzJYDY
-
-
Mashup Score: 0Advantages of Using Novel Imaging in nmCRPC APCCC 2022 Presentation - Michael Morris - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Michael Morris presents on advantages of using novel imaging in nmCRPC. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section Head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA….
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Advantages of using novel imaging in #nmCRPC. #APCCC22 presentation by @morr316 @MSKCancerCenter. #WatchNow on UroToday > https://t.co/MRrDZvYFTf @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/pmciyCt6UI
-
PSMA ligand positron emission tomography disease extent and OS in patients with high-risk #nmCRPC: an international multicenter retrospective study. Presented by @ProfHadaschik @unidue. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/41tNFz8hpu @ASCO https://t.co/pgFxYOwjOw